Revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
Serina Therapeutics, Inc. (SER)
Price—Loading quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $130,000 | $56,000 | $3.2M | $34,000 | $144,000 | $361,000 | $1.7M | $1.4M | $1.4M |
| Gross profit | — | — | $102,000 | $21,000 | $125,000 | $335,000 | $1.5M | $1.0M | $1.2M |
| Gross margin | — | — | 3.24% | 61.76% | 86.81% | 92.80% | 85.88% | 73.93% | 88.03% |
| Research & development | $13.2M | $7.5M | $2.4M | $1.0M | $1.5M | $3.7M | $5.9M | $5.8M | $5.8M |
| Operating expenses | $24.2M | $17.1M | $6.3M | $7.0M | $8.2M | $10.4M | $14.0M | $12.3M | $9.7M |
| Operating income | −$24.0M | −$17.0M | −$3.1M | −$7.0M | −$7.9M | −$10.1M | −$12.6M | −$11.2M | −$6.7M |
| Operating margin | −18,478.46% | −30,442.86% | −99.24% | −20,514.71% | −5,509.03% | −2,797.78% | −726.79% | −805.52% | −474.57% |
| EBITDA | −$23.9M | −$16.9M | −$3.0M | −$2.6M | — | −$9.4M | −$12.2M | −$11.2M | −$6.0M |
| EBITDA margin | −18,401.54% | −30,264.29% | −96.38% | −7,661.64% | — | −2,604.16% | −704.05% | −801.36% | −426.00% |
| Net income | −$19.2M | −$11.1M | $5.3M | −$10.5M | −$8.7M | −$10.9M | −$12.2M | −$7.5M | −$6.6M |
| Net profit margin | −14,755.38% | −19,894.64% | 167.11% | −30,770.59% | −6,024.31% | −3,009.70% | −703.36% | −537.39% | −468.66% |
| Basic EPSper basic share | -$1.91 | -$1.51 | $83.00 | -$12,012.43 | -$10,017.61 | -$12,630.90 | -$14,373.09 | -$9,146.51 | -$9,146.51 |
| Diluted EPSper diluted share | -$1.91 | -$1.51 | $25.67 | -$12,012.43 | -$10,017.61 | -$12,630.90 | -$14,373.09 | -$9,146.51 | -$9,146.51 |
Owners
Reported shareholders
≈23.76%of listed shares
Juvenescence Ltd6.03M shares · Jan 31, 2025
View holders
| Holder | % owned |
|---|---|
Juvenescence Ltd | ≈23.76%6.03M shares |
Sio Capital Management, LLC | 3.94%1M shares |
Venkatesan Jay | ≈0.91%232.29K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.64%162.2K shares |
Waverly Advisors, LLC | 0.27%67.49K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.20%51.01K shares |
MINTZ STEVEN | ≈0.15%38.23K shares |
WILSON KAREN J | ≈0.12%30.1K shares |
Keel Point, LLC | 0.08%21.51K shares |
NORTHERN TRUST CORP | 0.08%20.77K shares |
VANGUARD FIDUCIARY TRUST CO | 0.08%20.01K shares |
Avidian Wealth Enterprises, LLC | 0.07%18.8K shares |
JANE STREET GROUP, LLC | 0.06%15.44K shares |
STATE STREET CORP | 0.05%12.76K shares |
Marshall Richard Peter | ≈0.05%12.18K shares |
LEDGER STEVEN A | ≈0.04%10.1K shares |
Caitong International Asset Management Co., Ltd | 0.01%3.74K shares |
WELLS FARGO & COMPANY/MN | 0.01%3.61K shares |
Tower Research Capital LLC (TRC) | 0.01%2.57K shares |
BlackRock, Inc. | <0.01%2.38K shares |
Percentages use 25.4M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 12, 2026Form 4 | WILSON KAREN JDirector | BuyCommon Stock | 5.0K | $1.77 | $8.8K | 10.1K |
| Jun 11, 2026Form 4 | WILSON KAREN JDirector | BuyCommon Stock | 5.1K | $1.75 | $8.9K | 5.1K |
| May 22, 2026Form 4 | Venkatesan JayDirector | BuyCommon Stock | 589 | $1.78 | $1.0K | 589 |
| May 22, 2026Form 4 | WILSON KAREN JDirector | BuyCommon Stock | 10.0K | $1.93 | $19.3K | 20.0K |
| May 21, 2026Form 4 | WILSON KAREN JDirector | BuyCommon Stock | 10.0K | $1.77 | $17.7K | 10.0K |